|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Nine tumors (20%) had increased c-MYC gene copy number (three to 8 copies).
|
10323217 |
1999 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Quinazoline derivative QPB-15e stabilizes the c-myc promoter G-quadruplex and inhibits tumor growth in vivo.
|
27144522 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
It is of interest that deletions of the first exon and hypomethylation of the c-myc gene have usually been observed only in some neoplasias.
|
1923512 |
1991 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In one case with a MYC break we obtained a novel MYC-SOCS1 translocation representing an unusual translocation of a proto-oncogene with a tumor suppressor gene.
|
27356265 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
MYC rearrangements are associated with a significant increase of MYC expression that is monoallelic, but MM tumors lacking a rearrangement have biallelic MYC expression at significantly higher levels than in MGUS.
|
24518206 |
2014 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breakpoints outside the switch mu (S mu) region (ie, the HindIII fragment encompassing S mu) on chromosome 14 were twice as common overall (73%) as those within S mu (27%), but in the 15 tumors with S mu breakpoints, 13 (87%) had a rearranged c-myc gene.
|
1849033 |
1991 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Interestingly, only one tumor with an unrearranged c-myc gene joined to the S mu region of chromosome 14 was observed.
|
1317726 |
1992 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
ANXA2 high expression tumors enriched DNA repair-related gene sets (DNA repair; P = .011, p53 pathway; P = .036) and cell proliferation-related gene sets (MYC targets; P = .041).
|
31171367 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Moreover, two tumors presented a pathogenic mutation in MYC exon 2 (rs28933407).
|
25200035 |
2015 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Two cell lines and one tumor carried alterations in all three genes, one cell line carried alterations of c-MYC and p53, and one primary tumor and one cell line carried p53 mutations and the t(14;18).
|
8274734 |
1994 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
FISH showed IGH, BCL2 and BCL6 rearrangements in 59%, 47% and 11% of cases, respectively, and MYC rearrangement in 5% of FL3A tumours and 25% of FL3B tumours.
|
23631722 |
2013 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In this pilot study, c-myc amplification was predictive for outcome, especially among patients with node-negative disease or steroid receptor-positive tumors; 51 and 46% differences in actuarial 5-year recurrence rates when compared to patients with tumors with normal c-myc gene copy numbers, respectively.
|
1737370 |
1992 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
It is unusual to find both t(14;18) and C-MYC translocation in the same tumour; those cases in which it has been described include examples of high-grade B-cell NHL (either de novo or transformed FL) or B-cell acute lymphoblastic lymphoma.
|
18297523 |
2008 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In some instances, however, these tumors contain variant translocations with breakpoints located more distant from and downstream of MYC, in a domain commonly known as pvt-1.
|
2470097 |
1989 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
MYC rearrangements were more common in Epstein-Barr virus (EBV)-positive (14 of 19, 74%) than EBV-negative (9 of 21, 43%) tumors (P<0.05).
|
20962620 |
2010 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
B-cell lymphomas with MYC/8q24 rearrangement and IGH@BCL2/t(14;18)(q32;q21), also known as double-hit or MYC/BCL2 B-cell lymphomas, are uncommon neoplasms.
|
22002575 |
2012 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Conversely, peripheral tumor cysts were found more frequently in ATRT-SHH (71%) and ATRT-TYR (94%) compared with ATRT-MYC (40%, P < 0.05).
|
30010851 |
2018 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Deregulated c-myc expression, as a consequence of translocation of the c-myc gene to one of the immunoglobulin loci, appears to play an important role in the pathogenesis of several B-cell tumors, including Burkitt's lymphoma, mouse plasmacytoma and rat immunocytoma.
|
1563831 |
1992 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Beyond Gleason Score, Prostate Serum Antigen and tumor stage, nowadays there are no biological prognostic factors to discriminate between indolent and aggressive tumors.The most common known genomic alterations are the TMPRSS-ETS translocation and mutations in the PI3K, MAPK pathways and in p53, RB and c-MYC genes.The aim of this retrospective study was to identify by next generation sequencing the most frequent genetic variations (GVs) in localized and locally advanced PCa underwent prostatectomy and to investigate their correlation with clinical-pathological variables and disease progression.
|
26887047 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Interestingly, however, the tumor contained c-myc gene rearrangement.
|
9661927 |
1998 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
No significant association was observed between the amplification in the MYC locus and the different clinicopathological parameters except for tumor differentiation.
|
16325511 |
2005 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Distribution of the c-MYC gene product in colorectal neoplasia.
|
26826706 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Finally, additional CIN-tumor-associated DNA amplifications were identified for EXT1 (8q24.11) and MYC (8q24.12) as well as DNA deletions for MAP2K5 (15q23) and LAMA3 (18q11.2).
|
17143621 |
2007 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We show that, despite their distal location in MYC, mutations in this region precisely phenocopy those in MbI in terms of stability, in vitro transformation, growth-promoting properties, in vivo tumorigenesis and ability to escape p53-dependent tumor surveillance mechanisms.
|
24998853 |
2015 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
An IGH-MYC gene fusion indicating the presence of a typical Burkitt translocation t(8;14)(q24;q32) in the tumor tissue was detected by fluorescent in situ hybridization.
|
20799767 |
2010 |